环孢素A联合激素冲击治疗原发性肾病综合征的临床疗效分析

Analysis of Clinical Curative Effect of Cyclosporin A Combined with Hormone in Treatment of Primary Nephrotic Syndrome

目的研究环孢素A联合激素冲击治疗原发性肾病综合征的临床效果。方法将该院收治的79例原发性肾病综合征患者作为该次研究病例,病例选取时间为2014年11月—2016年9月,按照计算机表法将其分为研究组(n=40)和对照组(n=39),对照组行常规治疗,并加用激素冲击治疗,研究组行环孢素A联合激素冲击治疗,并对患者进行随访,分析两组患者的临床治疗效果,并比较两组患者的Alb与24小时尿蛋白情况。结果研究组完全缓解26例,显著缓解13例,部分缓解9例,临床总有效率为95.00%,对照组完全缓解17例,显著缓解5例,部分缓解8例,临床总有效率为76.92%(χ~2=5.383 9),研究组与对照组患者治疗后Alb与24小时尿蛋白与治疗前比较明显降低,两组治疗后Alb与24小时尿蛋白值比较差异有统计学意义(t=15.8925,7.969 1)。结论环孢素A联合激素冲击治疗原发性肾病综合征的效果显著,能够有效减少患者的24小时尿蛋白,且总有效率高,值得临床推广应用。

Objective To study the clinical effect of Cyclosporin A combined with hormone in treatment of primary nephrotic syndrome. Methods 79 cases of patients with Primary nephrotic syndrome admitted and treated in our hospital from November 2014 to September 2016 were selected and randomly divided into two groups, the control group with39 cases used the routine therapy, and hormone impulse therapy, while the research group with 40 cases used the cyclosporin A combined with hormone impulse therapy, and the patients were followed up, and the clinical treatment effect, Alb and 24 h urinary protein were compared. Results In the research group, 26 cases were relieved, and 13 cases were obviously relieved, 9 cases were partially relieved, and the total clinical effective rate was 95.00%, in the control group, 17 cases were totally relieved, 5 cases were obviously relieved, and 8 cases were partially relieved, and the total clinical effective rate was 76.92%（χ2=5.383 9）, after treatment, the Alb and 24 h urinary protein in the two groups obviously decreased compared with those before treatment, after treatment, the differences in the Alb and 24 h urinary protein between the two groups were obvious with statistical significance（t=15.892 5,7.969 1）. Conclusion The effect of cyclosporin A combined with hormone in treatment of Primary nephrotic syndrome is obvious, which can effectively reduce the 24 h urinary protein with high total effective rate, and it is worth clinical promotion and application.